Muse bio appoints genomics industry expert, John Stuelpnagel, as Chairman of the Board of Directors

Boulder CO – February 28, 2017 - Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

Muse bio secures $23M Series B financing led by Venrock

Boulder, CO – February 28, 2017 – Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

Muse bio appoints proven biotech industry executive and innovator, Kevin Ness, as CEO

Kevin Ness brings expertise in commercializing innovative products for the biotechnology industry

Boulder, CO – December 7, 2016 – Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors.